The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Factor XI Antisense Oligonucleotide for Prevention of Venous Thrombosis
Open accessAbstract
BACKGROUND: Experimental data indicate that reducing factor XI levels attenuates thrombosis without causing bleeding, but the role of factor XI in the prevention of postoperative venous thrombosis in humans is unknown. FXI-ASO (ISIS 416858) is a second-generation antisense oligonucleotide that specifically reduces factor XI levels. We compared the efficacy and safety of FXI-ASO with those of enoxaparin in patients undergoing total knee arthroplasty. METHODS: In this open-label, parallel-group study, we randomly assigned 300 patients who were undergoing elective primary unilateral total knee arthroplasty to receive one of two doses of FXI-ASO (200 mg or 300 mg) or 40 mg of enoxaparin once daily. The primary efficacy outcome was the incidence of venous thromboembolism (assessed by mandatory bilateral venography or report of symptomatic events). The principal safety outcome was major or clinically relevant nonmajor bleeding. RESULTS: Around the time of surgery, the mean (±SE) factor XI levels were 0.38±0.01 units per milliliter in the 200-mg FXI-ASO group, 0.20±0.01 units per milliliter in the 300-mg FXI-ASO group, and 0.93±0.02 units per milliliter in the enoxaparin group. The primary efficacy outcome occurred in 36 of 134 patients (27%) who received the 200-mg dose of FXI-ASO and in 3 of 71 patients (4%) who received the 300-mg dose of FXI-ASO, as compared with 21 of 69 patients (30%) who received enoxaparin. The 200-mg regimen was noninferior, and the 300-mg regimen was superior, to enoxaparin (P<0.001). Bleeding occurred in 3%, 3%, and 8% of the patients in the three study groups, respectively. CONCLUSIONS: This study showed that factor XI contributes to postoperative venous thromboembolism; reducing factor XI levels in patients undergoing elective primary unilateral total knee arthroplasty was an effective method for its prevention and appeared to be safe with respect to the risk of bleeding. (Funded by Isis Pharmaceuticals; FXI-ASO TKA ClinicalTrials.gov number, NCT01713361.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Kearon (2012) · doi:10.1378/chest.11-2301 · Cited by 6,119
Kahn (2012) · doi:10.1378/chest.11-2296 · Cited by 2,693
Prevention of VTE in Orthopedic Surgery Patients
Falck-Ytter, Y., Francis, C. W., Johanson, N. A., Curley, C., Dahl, O. E., Schulman, S., Ortel, T. L., Pauker, S. G., & Colwell, C. W. (2012) · Chest · doi:10.1378/chest.11-2404 · Cited by 1,930
Triggers, targets and treatments for thrombosis
Mackman, N. (2008) · Nature · doi:10.1038/nature06797 · Cited by 1,188
Thrombosis: tangled up in NETs
Martinod, K., & Wagner, D. D. (2014) · Blood · doi:10.1182/blood-2013-10-463646 · Cited by 866
Platelet Polyphosphates Are Proinflammatory and Procoagulant Mediators In Vivo
Müller, F., Mutch, N. J., Schenk, W. A., Smith, S. A., Esterl, L., Spronk, H. M., Schmidbauer, S., Gahl, W. A., Morrissey, J. H., & Renné, T. (2009) · Cell · doi:10.1016/j.cell.2009.11.001 · Cited by 831
Factor XI Activation in a Revised Model of Blood Coagulation
Gailani, D., & Broze, G. J. (1991) · Science · doi:10.1126/science.1652157 · Cited by 775
Self-citationHigh Levels of Coagulation Factor XI as a Risk Factor for Venous Thrombosis
Meijers, J. C. M., Tekelenburg, W. L. H., Bouma, B. N., Bertina, R. M., & Rosendaal, F. R. (2000) · New England Journal of Medicine · doi:10.1056/nejm200003093421004 · Cited by 700
Extracellular RNA constitutes a natural procoagulant cofactor in blood coagulation
Kannemeier, C., Shibamiya, A., Nakazawa, F., Trusheim, H., Ruppert, C., Markart, P., Song, Y., Tzima, E., Kennerknecht, E., Niepmann, M., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0608647104 · Cited by 535
Idraparinux versus Standard Therapy for Venous Thromboembolic Disease
(2007) · New England Journal of Medicine · doi:10.1056/nejmoa064247 · Cited by 335
Tucker, E. I., Marzec, U. M., White, T. C., Hurst, S., Rugonyi, S., McCarty, O. J. T., Gailani, D., Gruber, A., & Hanson, S. R. (2009) · Blood · doi:10.1182/blood-2008-06-163675 · Cited by 204
Self-citationZhang, H., Löwenberg, E. C., Crosby, J. R., MacLeod, A. R., Zhao, C., Gao, D., Black, C., Revenko, A. S., Meijers, J. C. M., Stroes, E. S., et al. (2010) · Blood · doi:10.1182/blood-2010-04-277798 · Cited by 203
Self-citationCushman, M., O’Meara, E. S., Folsom, A. R., & Heckbert, S. R. (2009) · Blood · doi:10.1182/blood-2009-05-219915 · Cited by 142
Effects of factor XI deficiency on ferric chloride‐induced vena cava thrombosis in mice
Wang, X., SMITH, P. L., HSU, M., Gailani, D., Schumacher, W. A., Ogletree, M. L., & Seiffert, D. (2006) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2006.02093.x · Cited by 138
Self-citationFuji, T., FUJITA, S., TACHIBANA, S., & Kawai, Y. (2010) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2010.04021.x · Cited by 137
Antithrombotic Effect of Antisense Factor XI Oligonucleotide Treatment in Primates
Crosby, J. R., Marzec, U. M., Revenko, A. S., Zhao, C., Gao, D., Matafonov, A., Gailani, D., MacLeod, A. R., Tucker, E. I., Gruber, A., et al. (2013) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.113.301282 · Cited by 128
Self-citationYounis, H. S., Crosby, J. R., Huh, J.-I., Lee, H. S., Rime, S., Monia, B. P., & Henry, S. P. (2012) · Blood · doi:10.1182/blood-2011-10-387134 · Cited by 85
Self-citationGunn, S., Sonesson, E., Peerlinck, K., Vanassche, T., Vandenbriele, C., Ageno, W., Glazer, S., Prins, M. H., Buller, H. R., Tangelder, M. J. D., et al. (2013) · Thrombosis and Haemostasis · doi:10.1160/th13-01-0066 · Cited by 16
Self-citation
Cited by
Long Noncoding RNAs in Cancer Pathways
Schmitt, A. M., & Chang, H. Y. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.03.010 · Cited by 2,992
Antithrombotic Therapy for Atrial Fibrillation
Lip, G. Y. H., Banerjee, A., Boriani, G., Chiang, C. E., Fargo, R., Freedman, B., Lane, D. A., Ruff, C. T., Turakhia, M., Werring, D., et al. (2018) · Chest · doi:10.1016/j.chest.2018.07.040 · Cited by 939
The delivery of therapeutic oligonucleotides
Juliano, R. L. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkw236 · Cited by 854
Crooke, S. T., Witztum, J. L., Bennett, C. F., & Baker, B. F. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2018.03.004 · Cited by 841
Antisense technology: an overview and prospectus
Crooke, S. T., Baker, B. F., Crooke, R. M., & Liang, X.-H. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00162-z · Cited by 775
Metadata
- Authors
- Büller, H. R., Bethune, C., Bhanot, S., Gailani, D., Monia, B. P., Raskob, G. E., Segers, A., Verhamme, P., & Weitz, J. I.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2015-01-15
- Volume
- 372
- Issue
- 3
- Pages
- 232-240
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2102719739
- Cited by
- 630
- References
- 18
- FWCI
- 39.47
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.